The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I hold a handful of stocks which are on the back burner, Vela is where I focus my attention tho (clearly). I also hold some crypto, precious metals, property, so relatively well diverted
In terms of my price calculations, I’m literally providing a realistic outcome if the trial is successful. All figures in my previous comment can be verified
May i suggest a chill pill today Posty, lol
To go back to a theoretical mathematical equation from the other day:
Vela's mcap is currently £10m @ 0.08p
Vela holds an 8% stake in the SGS Arcadia trial
If successful, an oral Covid treatment drug can produce a revenue of £1b per year
This would mean that Vela's slice would be worth £80m annually, without considering the sale of rights
So if Vela's £10m mcap had an extra £80m dropped on top of it, we could be looking at some serious gains
And this is only from one of JN's strategical investments
I'm expecting the initial results to land anytime after this Friday, with that date being 4 weeks after the trial was finalised
I agree that Vela is currently unloved, however there have certainly been MM games going on
Early yesterday the price was 10% down (possibly taking stop losses) and then finished flat
Already today we've seen swings in the price from -7% down (on low sell volume) to +5% up
This kind of price action isn't normal
Also, good to see some new faces on the board
SGS have just liked my comment from May... feeling bullish ;)
https://twitter.com/st_capital/status/1392450612302946305?s=21
Tech, W e’ll see how the next few weeks go aye and I’ll keep the board up to date with my TA
And after criticising me the other day you never gave feedback on my response. You called me out for saying the trader likely done it for personal reason, which I think is a fair assumption. Then you suggested that it was down to insider trading, which is a far more unrealistic scenario
Good to see you back Mick
Still bullish on the chart, respecting the upward trend line. Shouldn't be long before we blast through
https://www.tradingview.com/x/KhJ1HBT3/
The wait is almost over and lots of us are extremely optimistic (for good reason)
We may see some shakiness in the SP this week in an attempt to take shares from weak hands. Those who do cave in and sell will be kicking themselves when the news arrives
Good luck all
Professor John Martin, Chairman of the charity and Principal Investigator on the grant awarded by UKRI, said:
“Novel research thinking in an interdisciplinary group combined with the drive of the charity and the excellent relationship we have with Astra Zeneca have produced the potential for a great therapeutic leap. This also has potential for non-diabetic patients with COVD-19.”
David Tapolczay, CEO St George Street, also said:
“Given the current crisis, we have paused all our current research programmes to focus totally on this clinical trial and evaluate this potentially life-saving new drug. Our charity was set up to accelerate the delivery of treatments to patients and this ethos is needed now more than ever before. We want to do everything in our power to ensure patients recover from this terrible virus.”
in December*
Dave Tapolczay, CEO of SGS said:
"We are delighted with the progress of the ARCADIA trial. Obviously the news that we will shortly have vaccines available is very welcome, but it doesn't remove the need for treatments for COVID-19, especially for those with underlying conditions such as diabetes. In some cases, the vaccines will not be suitable for people with those conditions, in other cases the vaccine may not be 100% effective. Add to this the fact that uptake and supply of the vaccine may not be optimal, and it is highly likely that treatments will be needed for many years to come. Nobody should assume there will be only one way out of this pandemic. Certainly, big pharma companies want to offer a full suite of products for any disease area whether vaccine, prophylaxis, therapeutic, and for recovery. Unlike many other treatments AZD1656 is not virus specific, as it is activating cells within our own body. This gives the treatment an advantage over many other treatments, and potentially it could be used in other virally induced respiratory diseases including other mutations of coronavirus, MERS and pneumonia. This gives AZD1656 longevity as a treatment beyond the current pandemic. AZD1656 is an orally available tablet that is stable at room temperature, making it suitable for use around the world. Furthermore, should the trial be successful, we expect to agree a commercial deal with a partner almost immediately."
Professor Evans said:
“All of us supporting this trial recognise this drug has the potential to make a huge difference to people with diabetes who are unfortunate enough to contract coronavirus and we foresee a significant impact on the level of fatalities in the future. Treatments such as this could be vital as we are likely to be living with this horrific virus for some time to come.”
Imagine what a super RNS like that would do for Vela. I actually makes a lot of sense that commercialisation talks have begun when you consider the unusual gap between RNSs and the positive feedback we’ve already received about the drug in June
I completely trust JN's judgement, his track record is great and what he's done for Vela so far has improved the company massively
Like most holders here i'm happy to wait for those all important results, whether they come this week or in two weeks time
Very interested to see the price action over the next few days. As somebody stated recently we could see some MM games with SP as we anticipate the SGS initial results
We’re also seeing the de-rampers re-emerge from under their rocks, armed with negativity and baseless claims
The fundamentals speak for themselves
I’m curious to why the price didn’t tank (or rise) as soon as the trade was taken at 15:52, smells a bit fishy to me
However, I am confident that whoever did make the trade done it for their own personal reasons, which could be down to needing the cash, being over exposed, maybe even top slicing after accumulating at 0.07p, who knows
We know JN runs a very tight ship and the SGS trial is a double blind, so whoever it was can’t know something which we don’t, they did it based on their own strategy which is completely fair
Although I’m confident that it is a sell, there is a small possibility that it could be a buy when you consider just 1.5 hours earlier sells we’re going through at 0.0715p, and as we know MM’s sometimes offer better prices for large quantities
Regardless I remain completely confident with the fundamentals and the price action on the charts. Looking forward to next week as anticipation for results builds :)